EDN1 and COVID-19: In addition, studies have shown that the patients with severe COVID-19 exhibit elevated levels of autoantibodies against the endothelin-1 type A receptor (ETAR), which mimic ET-1 and cause sustained vasoconstriction and inflammation [35].